Nantkwest Inc (NASDAQ:NK) has been given an average rating of “Hold” by the six brokerages that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating and four have given a hold rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $3.50.
A number of analysts have commented on the stock. Zacks Investment Research downgraded shares of Nantkwest from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Raymond James Financial reiterated a “hold” rating on shares of Nantkwest in a report on Monday, December 11th. Finally, BidaskClub upgraded shares of Nantkwest from a “sell” rating to a “hold” rating in a report on Tuesday, March 6th.
A number of institutional investors have recently bought and sold shares of the stock. Vident Investment Advisory LLC increased its holdings in Nantkwest by 40.3% in the 4th quarter. Vident Investment Advisory LLC now owns 262,014 shares of the biotechnology company’s stock valued at $1,176,000 after purchasing an additional 75,201 shares during the last quarter. Ardsley Advisory Partners acquired a new stake in Nantkwest in the 4th quarter valued at approximately $112,000. Deutsche Bank AG increased its holdings in Nantkwest by 116.7% in the 4th quarter. Deutsche Bank AG now owns 67,847 shares of the biotechnology company’s stock valued at $304,000 after purchasing an additional 36,542 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Nantkwest by 23.2% in the 4th quarter. Renaissance Technologies LLC now owns 232,900 shares of the biotechnology company’s stock valued at $1,046,000 after purchasing an additional 43,800 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Nantkwest by 155.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 25,579 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 71,444 shares during the last quarter. Hedge funds and other institutional investors own 15.89% of the company’s stock.
WARNING: This article was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3338360/brokerages-set-nantkwest-inc-nk-target-price-at-3-50.html.
NantKwest, Inc is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.